CR20250247A - Agonistas triples de los receptores de glp1/gip/npy2 - Google Patents

Agonistas triples de los receptores de glp1/gip/npy2

Info

Publication number
CR20250247A
CR20250247A CR20250247A CR20250247A CR20250247A CR 20250247 A CR20250247 A CR 20250247A CR 20250247 A CR20250247 A CR 20250247A CR 20250247 A CR20250247 A CR 20250247A CR 20250247 A CR20250247 A CR 20250247A
Authority
CR
Costa Rica
Prior art keywords
gip
agonists
glp1
npy2
receptors
Prior art date
Application number
CR20250247A
Other languages
English (en)
Inventor
Peter Wilhelm Haebel
Robert Augustin
Daniel Paul Teufel
Charlotte Stahl Madsen
Anthony Murray
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20250247A publication Critical patent/CR20250247A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Polipéptidos híbridos agonistas de los receptores de GIP, GLP-1 y del neuropéptido Y2 (NPY2) y su uso médico en el tratamiento de una variedad de enfermedades, condiciones o trastornos, tales como obesidad, diabetes, y/o NASH. Los polipéptidos tienen la estructura general Z1-Z2-Z3, donde Z1 es un polipéptido híbrido que agoniza a GIPR y GLP1R, Z2 es un conector, y Z3 es un polipéptido que agoniza a hY2R.
CR20250247A 2022-12-21 2023-12-20 Agonistas triples de los receptores de glp1/gip/npy2 CR20250247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22215510 2022-12-21
PCT/EP2023/086825 WO2024133382A1 (en) 2022-12-21 2023-12-20 Glp1/gip/npy2 receptor triple agonists

Publications (1)

Publication Number Publication Date
CR20250247A true CR20250247A (es) 2025-08-18

Family

ID=84568898

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250247A CR20250247A (es) 2022-12-21 2023-12-20 Agonistas triples de los receptores de glp1/gip/npy2

Country Status (17)

Country Link
US (1) US20240247080A1 (es)
EP (1) EP4638481A1 (es)
JP (1) JP2025542352A (es)
KR (1) KR20250124883A (es)
CN (2) CN120282980A (es)
AR (1) AR131430A1 (es)
AU (1) AU2023410450A1 (es)
CL (1) CL2025001595A1 (es)
CO (1) CO2025006891A2 (es)
CR (1) CR20250247A (es)
DO (1) DOP2025000153A (es)
IL (1) IL321394A (es)
JO (1) JOP20250151A1 (es)
MX (1) MX2025007172A (es)
PE (1) PE20252166A1 (es)
TW (1) TW202438512A (es)
WO (1) WO2024133382A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025257294A1 (en) 2024-06-13 2025-12-18 Boehringer Ingelheim International Gmbh Soluble glp1/gip/npy2 receptor triple agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2330124B1 (en) * 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
MX2012003939A (es) * 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
WO2017204219A1 (ja) * 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
US20190211072A1 (en) * 2018-01-10 2019-07-11 Syracuse University TRI-AGONIST FOR THE GLu, GLP-1 AND NPY2 RECEPTORS
AU2020206388B2 (en) * 2019-01-07 2022-12-01 Vitalixir (Beijing) Co., Ltd Novel polypeptide and therapeutic uses thereof
EP4058047A1 (en) * 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
AU2020397917A1 (en) * 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
UA130066C2 (uk) * 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
WO2022080986A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
CN116171164A (zh) * 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂

Also Published As

Publication number Publication date
US20240247080A1 (en) 2024-07-25
JP2025542352A (ja) 2025-12-25
AR131430A1 (es) 2025-03-19
WO2024133382A1 (en) 2024-06-27
CL2025001595A1 (es) 2025-09-12
JOP20250151A1 (ar) 2025-06-18
TW202438512A (zh) 2024-10-01
MX2025007172A (es) 2025-07-01
DOP2025000153A (es) 2025-07-31
EP4638481A1 (en) 2025-10-29
CN120282980A (zh) 2025-07-08
PE20252166A1 (es) 2025-09-04
KR20250124883A (ko) 2025-08-20
AU2023410450A1 (en) 2025-06-19
CN120865433A (zh) 2025-10-31
CO2025006891A2 (es) 2025-06-06
IL321394A (en) 2025-08-01

Similar Documents

Publication Publication Date Title
MX2021000793A (es) Compuestos coagonistas de gip/glp1.
MX2021012277A (es) Agonista multireceptor y uso medico del mismo.
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
CL2025001595A1 (es) Agonistas triples de los receptores de glp1/gip/npy2
CL2023003794A1 (es) Agonista del receptor de glp-1 y composición y uso del mismo
PH12020551742A1 (en) Gip derivatives and uses thereof
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
CL2020002574A1 (es) Análogos novedosos de glp-1
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
CO2023000125A2 (es) Coagonistas de los receptores de glp-1 y gip
MX2020011007A (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado.
CL2023002639A1 (es) Composición farmacéutica y uso del agonista dual del receptor de gip y glp-1
MX2025008040A (es) Métodos para tratar el síndrome de sjögren primario con el uso de antagonistas fcrn
PE20251259A1 (es) Agonista dual de glp-1/gip, metodo de preparacion y uso del mismo
TR201900959T4 (en) COMPOSITIONS AND ITS MEDICAL USE.
CO2022004572A2 (es) Tratamiento de la diabetes mellitus tipo 2
PE20251599A1 (es) Metodos para el tratamiento de la obesidad
CO2021018031A2 (es) Una composición farmacéutica para la diabetes mellitus
EA202092891A1 (ru) Соединения-коагонисты gip/glp1